AMCP 2020 Policy and Advocacy Focus Areas

Rising Cost of Pharmaceuticals and Price Transparency

- Advocate for increased availability and access to affordable medications and therapies, including newly approved, high investment medications and digital therapeutics.
- Ensure patient access to affordable alternatives, including biosimilars and generics.
- Promote meaningful transparency on drug pricing and patient cost-sharing.
- Continue to build on and message AMCP’s efforts to reduce health care costs through an ongoing evaluation of drug pricing strategies to ensure proposals to modify the prescription drug reimbursement system are comprehensive in nature.
- Conduct a comprehensive evaluation of the current prescription drug reimbursement system to evaluate opportunities to improve efficiencies and transparency, which includes the assessment of manufacturer rebates, pass through pricing, and competitively priced contracting.

Shift from Fee-For Service to Value-Based Care

- Advocate for the development of clear metrics to shift payment for pharmaceuticals and other treatments from fee-for-services (FFS) to value-based care.
- Promote the use of value-based contracting.
- Encourage ways to facilitate data sharing and interoperability of electronic health records to evaluate outcomes while ensuring privacy protections for patients.
- Advocate for increased patient access to pharmacists and team-based integrated care.
- Continue to advocate for Preapproval Health Care Economic Information (HCEI) sharing.

Managed Care Pharmacy Strategies

- Promote the use of managed care pharmacy strategies such as prior-authorization and step therapy in public and private programs, including Medicare Part D, Medicare Part B, and Medicaid.
- Advocate for AMCP’s position regarding tier restrictions and coverage mandates in public and private programs, including Medicare Part D, Medicare Part B and Medicaid.
- Lead the dialogue on prior authorization best practices and utilization without overburdening the healthcare system.